Total brain t2-hyperintense lesion-volume and the axonal damage in the normal-appearing white matter of brainstem in early relapsing-remitting multiple sclerosis;Relación entre el volumen lesional cerebral total en resonancia magnética secuencia T2 y el daño neuroaxonal en la sustancia blanca aparentemente normal del tronco del encéfalo en la esclerosis múltiple remitente-recurrente

Revista de Neurologia

Volumn 45, Issue 8, 2007, Pages 468-473

  Pascual Lozano, A M ^a   Martinez Bisbal M C ^b   Bosca Blasco I ^a   Valero Merino, C ^a   Coret Ferrer, F ^c   Marti Bonmati L ^d   Martinez Granados B ^b   Celda, B ^b   Casanova Estruch, B ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL QUIRÓN   (Spain)

Author keywords

Axonal damage; Choline; Creatine; Lesion load; Magnetic resonance imaging; MR spectroscopy; Multiple sclerosis; N acetylaspartate

Indexed keywords

ADULT; ARTICLE; AXONAL INJURY; BRAIN DAMAGE; CLINICAL ARTICLE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; SPECTROSCOPY;

EID: 37348998911     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4508.2007087     Document Type: Article

References (51)

1. De Stefano N, Guidi L, Stromillo ML, Bartolozzi ML, Federico A. Imaging neuronal and axonal degeneration in multiple sclerosis. Neurol Sci 2003; 24: S283-6.
2. De Stefano N, Bartolozzi ML, Guidi L, Stromillo ML, Federico A. Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis. J Neurol Sci 2005; 233: 203-8.
3. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295-302.
4. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65-70.
5. Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003; 126: 433-7.
6. Rovaris M, Gambini A, Gallo A, Falini A, Ghezzi A, Beneditti B, et al. Axonal injury in early multiple sclerosis is reversible and independent of short-term disease evolution. Neurology 2005; 65: 1626-30.
7. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9.
8. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 3338: 278-85.
9. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000; 123: 1174-83.
10. Martínez-Bisbal MC, Celda-Muñoz B, Martí- Bonmatí L, Casanova-Estruch B, Coret-Ferrer F. Diferencias en la espectroscopia de las lesiones de esclerosis múltiple en su forma remitente-recurrente mediante resonancia magnética. Rev Neurol 2002; 34: 807-12.
11. Hart BA, Bauer J, Muller HJ, Melchers B, Nicolay K, Brok H, et al. Histopathological characterization of magnetic resonance imaging-detectable brain white matter lesions in a primate model of multiple sclerosis: a correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus). Am J Pathol 1998; 153: 649-63.
12. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al. Multiple sclerosis and chronic autoinmmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157: 267-76.
13. Pelletier J, Suchet L, Witjas T, Habib M, Guttmann CR, Salamon G, et al. A longitudinal study of callosal atrophy and interhemisferic dysfunction in relapsing-remitting multiple sclerosis. Arch Neurol 2001; 58: 105-11.
14. Ranjeva JP, Pelletier J, Confort-Gouny S, Ibarrola D, Audoin B, Le Fur, et al. MRI/MRS of corpus callosum in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2003; 9: 554-65.
15. Casanova B, Martínez-Bisbal MC, Valero C, Celda B, Martí-Bonmatí L, Pascual A, et al. Evidence of wallerian degeneration in normal appearing white matter in the early stages of relapsing-remitting multiple sclerosis: a 1-HMRS study. J Neurol 2003; 250: 22-8.
16. Gadea M, Martínez-Bisbal MC, Martí-Bonmatí L, Espert R, Casanova B, Coret F, et al. Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis. Brain 2004; 127: 89-98.
17. Bjartmar C, Kidd G, Mörk S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893-901.
18. Bergers E, Bot JC, De Groot CJ, Polman CH, Lycklama A, Nijeholt GJ, et al. Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. Neurology 2002; 59: 1766-71.
19. Inglese M, Ge Y, Filippi M, Falini A, Grossman RS, Gonen O. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage 2004; 21: 1825-9.
20. Prinster A, Quarantelli M, Orefice G, Lanzillo R, Brunetti A, Mallica C, et al. Grey matter loss in relapsing-remitting multiple sclerosis. A voxel-based morphometry study. Neuroimage 2006; 29: 859-67.
21. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998; 121: 103-13.
22. Sarchielly P, Presciutti O, Pelliccioli GP, Tarducci R, Gobbi G, Chiarini P, et al. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 1999; 122: 513-21.
23. Trapp BD, Bo L, Mork S, Chang A. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 1999; 98: 49-56.
24. Lovas G, Szilágyi N, Májtényi K, Palkovits M, Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000; 123: 308-17.
25. Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000; 47: 391-5.
26. Bjartmar C, Wujet JR, Trapp BP. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003; 206: 165-71.
27. De Luca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 2004; 127: 1009-18.
28. Mainero C, De Stefano N, Iannucci G, Sormani MP, Guidi L, Federico A, et al. Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology 2001; 56: 1331-4.
29. 2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2002; 23: 371-5.
30. Kapeller P, McLean MA, Griffin CM, Chard D, Parker GJ, Barker GJ, et al. Preliminary evidence for neural damage in cortical grey matter and in normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. J Neurol 2001; 248: 131-8.
31. Chard DT, Griffin CM, McLean MA, Kapeller P, Kapoor R, Thompson AJ, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002; 125: 2342-52.
32. Tiberio M, Chard DT, Altmann DR, Davies G, Griffin CM, Malean MA, et al. Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study. Neurology 2005; 64: 1001-7.
33. Simmons ML, Frondoza CG, Coley JT. Immunocytochemical localization of N-acetyl aspartate with monoclonal antibodies. Neuroscience 1991; 45: 37-45.
34. Di Constanzo A, Trojsi F, Tosetti M, Giannatempo GM, Nemore F, Piccirillo M, et al. High-field proton MRS of human brain. Eur J Radiol 2003; 48: 146-53.
35. Poser CM, Paty DW, Scheinberg L. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
36. Barkhof F, Filippi M, Van Waesbergh JH, Campi A, Miller DH, Ader HJ. Interobserver agreement for diagnostic MRI criteria in suspected multiple sclerosis. Radiology 1999; 41: 347-50.
37. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 144-52.
38. Naressi A, Couturier C, Castang I, De Beer B, Graveron-Demilly D. Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med 2001; 31: 269-86.
39. Villanueva V, Álvarez-Linera J, Gómez-Garre P, Gutiérrez J, Serratosa JM. MRI volumetry and proton MR spectroscopy of the brain in Lafora disease. Epilepsia 2006; 47: 788-92.
40. Caramaros Z, Narayanan S, Arnold DL. 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain 2005; 128: 2483-506.
41. Allen IV, Glober G, Anderson R. Abnormalities in the macroscopically normal white matter in cases of mild or spinal multiple sclerosis (MS). Acta Neuropathol Suppl (Ber) 1981; 7: 176-8.
42. Allen IV, McQuaid S, Mirakhur M, Nevin G. Pathological abnormalities in the normal white matter in cases of mild or spinal multiple sclerosis. Neurol Sci 2001; 22: 141-4.
43. Davies SE, Newcombe J, Williams SR, McDonald WI, Clark D. High resolution proton NMR spectroscopy of multiple sclerosis. J Neurochem 1995; 64: 742-8.
44. Sijens PE, Mostert JP, Oudkerk M, De Keyser J. 1H-MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings. Eur Radiol 2006; 16: 489-95.
45. Li BS, Wang H, Gonen O. Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain spectroscopy. Magn Reson Imaging 2003; 21: 923-8.
46. Vrenken H, Barkhof F, Uitdehaag BM, Castelijns JA, Polman CH, Pouwels PJ. MR spectroscopic evidence for glial increase but not for neuroaxonal damage in MS normal-appearing white matter. Magn Reson Med 2005; 53: 256-66.
47. Mader I, Roser W, Kappos L, Hagberg G, Seelig J, Radue EW, et al. Serial proton MS spectroscopy of contrast enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol 2000; 21: 1220-7.
48. Degaonkar MN, Khubchandhani M, Dhawan JK, Jayasurdar R, Jagannathan NR. Sequential proton MRS study of brain metabolite changes monitored during a complete pathological cycle of demyelination and remyelination in a lysophosphatidyl choline (LPC)-induced experimental demyelinating lesion model. NMR Biomed 2002; 15: 293-300.
49. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-64.
50. Rovaris M, Agosta F, Sormani MP, Inglese M, Martinelli V, Comi G, et al. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. Brain 2003; 126: 2323-32.
51. Inglese M, Mancardi GL, Pagani E, Rocca MA, Murialdo A, Saccardi R, et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell trasplantation. J Neurol Neurosurg Psychiatry 2004; 75; 643-4.